Chanty registration number.. 1189246 Brit-PACT th Arthriti5 CfAwTknI BRITISH PSORIATIC ARTHRITIS CONSORTIUM TRUSTEES. REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026 D.R. Hicks <TEREO
British Psoriatlc Arthrltis Consortium Contents Page Trustees. Report IndePeent Examiner's Report Statement of Financial Activitie5 Compardtive St6tement of Financial Activities Statement of Financial Posltlon Notes to the nancal Statements 9-12 The following pages do not forni part of the statutory accounts.. Detailed Staternent of Financial Activities 13
British Psoriatic Arthrltls Consortlum Trustees. Report For The Year Ended 31 March 2026 The trLtstees present thelr report and the finaacial statements for rhe year efjded 31 March 2026. Objectlves and Actlvltles Alm$ and Objectlves "The oblett of the CIO 15 to relieve slckness and to preserve and protect good health for the put1£ benefit by promoting edical knowledge. and excellence through education and SearCh with particular reference to the dlseases of psorlasSs and psoriatic arthritis. Public Benefit In this financlal year. Brit-PACT continued lo progress Yiith its mission to support education and research Into P50riatlc arthritls IPsA} In the UK. We held another successful Annual Meeting in the hybrid forrnat at the BCEC. Birmlngham, on 10th October 2025 and it V4as organised and chaired by Prof Pauline Ho, Dr Muhamad Jaslm and Dr Ashley Elliot. 39 delegates attend the meetlng in person while another 24 attendees loinÈd in online. The meeting hlghllghts Included a presentstion by Dr Andrea DI Matteo about the use of ultrasound in p50riatic disease and how thar can help guide treatment declsions. We also 4 debate on the topk'The use of dual biologic therapy in PSA.. 15 thi5 required?. with Prof Bruce Kirkham speaking for the rnotlon and Dr WllliatH Tillett aryuing against the motion. Mr Andy Kelly provided an update on bÈhèlf of the Brit-PAcf Patient Partner5 and that was followed by an onlinè Ease presentation and discussion about the use of dual biologics by Prof Helena Marzo- Ortega. There were also presentations from BrIt-pA Researcher and Clinician Abstract Prize Wlnner5 and Runners up as well as updates regardlng the various Brit-PACT funded searCh projects. Excellent feedbèck was received for the meeting wlth 93% of the attendees rating the meetlng'highly relevant. to their educational needs while o further 4% felt that the meeting was 'mosily relevant, regarding thi5 objective. MO0er. In November 2025 we also had the StM)ndyloarthritis Golden Anniversary Meeting in Leed5. The purpose of It via5 to celebrate and review th& flve decade5 of 5cientiFic dlscovery. dinical progress, and collaborative partnershlps since the fr5t publicatlon on the sptrndyloarthritis ISpAI concept 50 years ago. The rneetlng was jolntly arranged L>y us and Brit-5pA. our sister oryanlsation which focuses on axial spondyloarthrftls. and wa5 chaired by Professors Philip Helliwell and Helena Marzo-ortega. This was a 2-day event with 100 attendees and it began on Thursday 27th NOVemr ÈvÈning with a warm and engaging Celebrètion Dinner. Prof Helliwell ènd Prof Marzo Ortega opened the evening ¥Ylth v4elcomin9 remarks and reflèttions on the history of the SpA contept. This was followed by an excellent talk frotn Prof lain McInnes, who explored how our understanding of SPA pathophysiology has evolved dramatically over the last 50 years. an(J what the future might hold for us. The annlversary meeting on Friday 28th November had presenta110ns from an outstandlng Ilne up of national and internatlonal experts, Èach highlighting key milestones and ernerglng directions in SpA research. The pSentationS covered the evolution of classification criteria, advances In (magingf the role of animal models in shaping scientific understanding. and tnajor developments in genebC5. Further sessions focused on axial and peripheral disease, the importance of iecognising skin involvement. the transfomatlon of treatment strategies over time. The meetlng concluded wlth forward-lookn9 discu55ions on future initiatives and research opportuniti, offer)ng an exciting glimpse of hat lies ahead. By bringing tether pioneers who shaped the field and innovators who are driving it forward. the Golden Anniversary Meedng proved to be a memorable celebration of progre55 and an inspiring foundation for the next chapter in SpA research. UR5urprisingly. excellent feedbark was ceiVed for this meetlng totr with 95% of the attendee5 ratlng the ffleeting'highly relevafit, to their educational need5 while a further 5% lelt that rhe meetln9 was'mosily relevant. regarding thi5 objectlve. The 8rit-PACT pilot research grant scheme continues as before and the award for this is n¢)w in rnemory of Or Oeepak Jadon. a valued member of the 8rit-PAcf steertng committee. who sadly died ln 2023. All grants submltted were asked to Inclut3e at least one of the'Top IO, items Identified in the James Lind Priority Setting Partner5hipi which had been funded and publlshed previously by Brit-PAcf. The applitant5 were also asked to address an issue of importance and relevance to psoriatic disease and in line with the aims and purposes of Brit-PACT. Four hlgh quality appli¢ation5 were received and one research grant of £1S.000 was awarded to a researcher at the Universlty of Manchester. We have also continued to support other research with external funding. The SEQUENCE projert, a multicentre observational study that was launthed in 2022 to understand Inequity of biologic5 preSCribng across the UK and had high engagement from the genÈral 8rit-PAcf membership. has now been eotnpleted. Updates on this study were provided by Dr Chadotte Gollins at the annual meeting In ottober 2025 and articles based on it have been published in Rheurnatologyi the flagship loijrnal of the British Society for Rheumatology. The White Swan projett involved using social rnedia data to understand the lived experience of people ¥vith psoriatic arthritis receiving biologic therapiÈ5 and weight Tnana9ement interventions. An update abotst this project was also presented by Dr James Kimpton at the annual tneeting in ottober 2025 and an abstract based on the findings was presented as a poster at the 8SR (British Society for Rheumatology) annual conference In April 2026. 8rit-PACT continues to prtsvide suptK)rt and updates to the BtISh Society for Rheumatology on Its actlvlties and provide5 support to subcommittees of the BSR such as recommendatlOn5 for biologic use In psoatIC arthritis. Page I
British Psoriatic Arthritis Consortium Trustees. Report {continued) For The Year Ended 31 March 2026 The trustees confirm that they have complied with the requirements of Section 17 of rhe Charitles Art 2011 to have due regard to the Charity Commisslon's guidance on public benefit. Achievements and Performanre Maln Athltsvéménts l. Psoriatic Arthritls Education for Health Care Professionals Brit-PAcf continues to conduct educational meetings for rheurnatology health care professiona15 and seeks to grow membÈrship with a wider spectrum of HCP5, including dermatolo9i5ts and allied health professionals. Our main educational events this year were the Artnual meeting in October 2025 and the Spondyloarthritis Golden Annlversary Meeting In November 2025. An update on behalf of the Charity was also presented as part of the Spondyloarthfitls Special Interest Group at the British Society for Rheumawiogy Annual Conference In April 2026. 2. Funding and supporting Psoriatic Arthritis Research 0rIng 2025 6rit-PACT has funded one research project which aims to answer research questions relevant to patlents wlth PSA. This year's Oeepak Jadon Pilot Research Gont awarded to Dr Stephanie ShDop-Worrall Iuniverslty of Manchester) for the project titled'The Obesity Conundrum.. Childhood obesity and titne to diègnosis and early outcome in Juvenile P50riatic Arthritis, and she presented a project update to the 8rit-PACT membership at the Annual meeting in October 2025. A project update bvas 41so presented at this meeting by Dr Steven Zhao (University of Manche5terl who had been awarded a pilot research grant *n 2024 for his proleci titled'Blood Biomarker for Timely Diagnosis of Psoriatic Arthrib5'. 3. Sharlng patient perspertive on living wlth psoriatic disease. The patient partner5 continue to share the patient perspective wtth clinicians and other healthcare profe55iona15 and ¢01Saborate var10us oryani5ations to inform research direction. One of the patient members of the Steering Comfflittee presented at the Annual Meetsng. The paiient group ha5 also advised on Psoriatic Arthritis consensus recommendation5 and engaged with various activities Including surveys, workshops and assisting with grant applicatlons and other enga9emenV involvement opportunities. Financial Re¥iew Reserves Policy The board of tfU5tees agree to run the charity with reserves sufficient to meet expenses for approxlmately one year. Structure Governanco and Managernent Govern4ng Document The charlty Is constituted as a Charitable Incorpooted Organisation ICIOI In England & Wales. The governing document of the charity is the constitution of the CIO as approved by the Charity Cotnmi55ion in England & Wales ICCEWI The governing document is dated 20 April 2020. There are no rÉstrSctions in the governing documents on the operation of the Charlty or on its investment powers other than those imposed by Charity La¥v. The truse$ arè all individuals. Tritst¢¢ Seledlon Methods The Brit-PACT constitution inc(KporatÈs elertions for major executive committee positions. The Executive ComFnittee Itrusteesl includes rheumatolo9lSts (both consultant5 and trainees), allled health professionals and patient partners. In line with the constitution of the Charity nominations are sought annually for new executive committÈÈ members as vacancies become available. Voting Is by a single vote of all member5 and the majority vole is taken as the definltlve resulf. Jn this calendar year there have been one retirement from the executive committee Ims Clare Allen), two tHÈmbers wÈre re- elected for a second term (Prof Pauline Ho and Dr Taniè Gudul and one nev4 medical member elected (Dr Carmel Stoberl. Dr Willliam Tille¢ was also elected as Chair of Brit-PACT and he look ovÈr thi5 role from Dr Nicola Gullick. Page 2
British Psoriatic Arthritls Consortium Trustees. Report (continued) For The Year Ended 31 March 2026 Reference and Admlrtlstratlve Detalls Trustees L Coats (resigned 10110120251 N Gullick P Helliwell T Gudu C Allen (resigned 10110120251 PHO A Kelly S Mukheriee RHUM J Bluett c stober (appointed IO/1012025} w rillett M Jaslm A Elllot J Patkham J Begham Charlty Numbèr l 189246 Prlndpal Address Department l. Wolfsofi Building Royal Unlted Hospital Bèth BAI 3NG Independent examiner DR Hi¢ks Chartered Accountants DR Hick5 Chartered Accountsnts 107 PeTrn Hill Road Bath BAI 3RU Page 3
British Psoriatic Arthritis Consortium Trustees, Report (continued) For The Year Ended 31 March 2026 Statement of Trustees. Responslbllltles The rrustees arè responsible for preparing the Trustees, Report and the financial statements in accordance with applicable law and United Kingdoffl Accounting Standards {Vnited Kingdom Generally Accepted Accountlng Praciicel- The law applicable to charltles in England and Wales requlres the trustees to prepare financial statements for each financial year which give a rrue and falr view of rhe state of affairs of the charity and of the incomlng resources and 3pplicatlon of resources of the charity for that period. In preparing the financial statements the trustees are required to.. • select suttable accounting policie5 and then apply them con515tentlyi obSee the methods and principles in the Charity SORP., make judgments and accounting esbrnates that are reasonable and prudent. and prepare the financial statements on the goln9 concern basls unless 5t Is inappropriate to presume that the charlty will continue in business, The trustees are responsible for keeping adequate accountlng cOlS which dlsclose wlth reasonable accuracy at anyt]me the financial position of the charity and to enable thetr to ensure that the accounts comply with the Charitie5 kt 2011, the Charlties {Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detectson of fraud and other irregularitie5. The trustees are responsible for the maintenante and Integrity of the corporate and financial Information Included on the charity's website. Legislation in the United Kingdom governing the preparation and dissÈmination of fin3n¢ial statements may differ from legislation In other Jurisdictions, The trustees, report was approved by the board of trustÈÈs and signed on its behair tjy.. S Mukherjee Trustee 161LOI2026 Page 4
British Psoriatlc Arthritis Consortium Independent Examiner's Report to the Trustees of British Psorlatlc Arthrltls Consortium For The Year Ended 31 March 2026 I report to the trustees on my exomination of the accouftts of British Psoriatic Arthrftis Consortium {the Trust) for the year ended 31 March 2026. R•sponslbllltles and Basls of Report As the charity trustees of the Trust you are sponsible for the preparatlon of the accounts in accordance with the requlrements of the Charities Act 2011 I-fhe Actl. I report in SpeCt of my examlnation of the Trust's accounts carded out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 14515}Ibl of the Act. Independent Examiner's Statement I have completed my examination. I confirm that no rnaterial rr+atters have come t(> my attention In Connect[ wlth the Èxamination giving me cause to belleve that in any rnaterial respect.. l. accounDng fftcord5 were not kept in respect of the Trust a5 reouired by section 130 or the Act; or 2. the accounts do not accord with those records,. or 3. the accounts do noi comply ¥Yith the applicable requirements contem1 the forrn and contents of accounts set out In the Charities IAccounts afjd Report51 Regulatlons 2008 other than any requirement that the accounts give a 'true and falr vlew, whlch Is not a matter cons6dered as part of an independent examinauon. I have no concerns and have come arross no other matters In connection with the examlnaknon to whlch attentlon should be drnwn In this report Sn order t(> enable a proper understanding of the accounts to be reached. (j L£ DR Hicks Chartered Accountants 0410812026 107 Penn Hill Road Bath BAI 3RU Page 5
British Psoriatic Arthritis Consortiurn Statement of Financial Activities For The Year Ended 31 March 2026 2026 2025 Unrestrlcted Restrlrted funds funds Total fund5 Total fund$ Notes INCOME AND ENDOWMENTS FROM: Donations and legacie5 other trading activltles Investrrents 213 60,000 308 213 142 60,000 308 25,000 246 60.52L 60,521 25.388 EXPEt4DITURE ON: Raising funds 170.0771 170,0771 165,8151 NET EXPENDITURE 19,5561 19,5561 140,4271 NET MOVEMENT IN FUNDS 19,5561 19,556} 140,4271 RECONCILIATION OF FUNDS- Total funds brought for*4ard 79,272 52,648 131,920 172,347 TOTAL FUNDS CARRIED FORWARD li 69,716 52,648 122,364 131.920 The notes on pages 9 to 12 form part or these flnancial starements. Pa9e 6
Britlsh Psoriatic Arthrltis Consortium Comparative Statement of Financial Actlvltles For The Year Ended 31 March 2026 202S Unrestrlcted Rèstrlct•d run41$ fund5 Total funds 14otes INCOME AND ENDOWMENTS FROM: OoD3tion$ and legacies Other tradlng actlvities Investrnents 142 25.000 246 142 25,000 246 25.388 25,388 EXPENDITURE ON: Ralslng funds 158.7651 {7,0501 165,8151 NET EXPE14DITURE 133.3771 {7,0501 140,427) NET MOVEMENT IN FUNDS RecoNCILIATION OF FUNDS: Total funds brought Forward 133,3771 {7.0501 140,4271 IL2.649 59.698 172,347 TOTAL FUNDS CARRIED FORWARD li 79.272 52.648 131,920 The notes on pages 9 to 12 forrn part of these financial 5tatement5. Page 7
British Psoriatic Arthritis Consortium Statement of Financlal Position As At 31 March 2026 2026 2025 Unr*stricted R¢strfctÈd funds funds Total funds Total funds Not•s CURRENT ASSETS Debtors Cash at bank and in hand 1,985 123,541 1,985 123,541 5,713 128.688 125.526 125,526 134.401 Credltors: Amounts Falllng Due Within One Year io {3,1621 13,1621 12.481) NET CURREt4T ASSETS (UABiLmes) 122,364 122,364 131.920 TOTAL Assrfs LESS CURRENT LIABILITIES 122,364 122,364 131.920 NET AsseTS 122.364 122,364 131.920 FUNDS OF THE CMARirY Restricted Funds Unrestricted Fund5 52,648 69,716 52,648 79,272 TOTAL FUNDS il 122,364 131,920 On behalf of the board S MukhÈrlee Trustee 1611012026 The notes on page$ 9 to 12 forn part of these financial statements. Page 8
British Psoriatic Arthrltls Consortium Notes to the Financial Statements For The Year Ended 31 March 2026 l. General Information Britlsh Psoriatic Arthritis Consortlum is a charitable incorporated organisation registered with the Charlty Commi$5ion, registered charity number 1189246. The principal address is Departtnent I, Wolfson Building. Royal United Hospitsl, Bath. BAI 3NG. 2. Accountlng Pollcles 2.1. Basi$ of Prparati•n of Flnanelal Statements The financial ststements have been prepared In actordante with the Charities SORP IFRS 1021 "Accounting and Reporting by Charitie5'. Statement of Recommended practi applicable to charifi@s preparing their accounts accordante with the Financsal Reporting Standard applicable In the VK and Republic of Ireland IFRS 1021 (effective I January 20191" Financial Reportlng Standard 102 'The Financlal Reporting Standard applicable in the UK and Republic of Ireland" and the Charities Act 2011. The charlty Is a Public Benefit Entity as deftned by FRS 102. 2.2. Golng Concem Dl$clgsur¢ The trustees have not Identiried any material uncertalntles Tated to events or conditions that may cast 51gnificant doubt about the chadty's ability to coThtinue as a golng concern. 2.3. Incomln9 Resourcos Nature of income Gross income peseThts the value, net of value added tax and discounts, of goods provided tD CUStorner5 and work carried our in respect of services provided to CU5tomer5. Categorles of Income Income Is categorised as income from exthange transactions Icontt7Ct incemel and income from non-exchange transactions Igiftsl. investment income and other incorne. Ineome from exchange transactions is received by the charlty for go$ or services supplied under cDntoct or where eDtitlement is sublett to fulfilling performance related condititsns. The incorne the charity receives is approximately equal in value to the goods or service5 supplied by rhe charity to the purchaser. Incorne from a non-exchange transaction is where the charity receives value from the donor without proVlg equal vèlue In exchallge, and includes donations of moneyi 9oods and servkes freely given without giving equal value in exchange. Income retognition "Income, whether from exchange or rK)n exchange transacUons. Is recognlsed in the ststement of financlal activities {SOFAI on a receivable basis, when a transaction or other eveft¢ results in an increase in the charity'5 assets or reductlon In Its liabilities and only when the charity ha5 legal entitlement. the Income is probable and can be measured reliably. Dlvldends are accrued when the shareholder's right to receive payrnent is established. Income subjett to terms and conditions which must be met before the charity Is entlued to the resources is not recognlsed untll the condition5 have been met. All Income is accounted for gross. before deducting any related fees or costs.. 2.4. Ro$ources Expènded Recognition of liabilities and expendltu A liability. and the related expendItu, is reeognised when a legal or constructive obligation exlsts as a result of a past event, and when it is more likely than not that a trdnsfer of economic benefits will be required In settlement. and when the atnount of the obligatlon can be measured or reliably estimated.. LSabilitie5 arlslng from future funding comrnitments and constructive ObligaOn5, including perfomance lated grants, where the tlmlng or rhe amount of the future expenditu required to settle the obligation are uncertain give rise to a provision in the accounts, which Is reviewed at the accountin9 year end. The provision is increased to reflect any in¢r2ases in liabilities. and Is decreased by the utilisatlon of any provlslon within rhe period, and reversed If any provision is no longer requlred. These movewnents are charged or credited to rhe SpeCtive funds and activities to which the provision relates. Page 9
British Psoriatic Arthritis Consortium Notes to the Financial Statements (continued) For The Year Ended 31 March 2026 2.5. Cash and Cash Equi¥alents Cash cash equivalents are b35ic fin6tTrcial assets and include cash in hand and deposits hdd at call with banks. other short-terrn highly liquid investments that mature in no more than the months from the date of acqulsition and are readily convertible to a known amount of cash with insignificaTrt risk of change in val, and bank overdrafts. 3. Income from Donations and Legaaes 2026 2025 Unrestrlcted Unrestrfcted funds funds Donations gifts 213 142 4. Income from Other Trading Activltles 2026 202S Unrestrleted Unrestricted funds funds Spon50r5hips 60.000 25,000 5. Investment Income 2026 2025 Unrestricted Unrestricted funds funds Bank intert recesvable 308 246 6. Analysis of Expenditure 1026 Actlvltles undertaken directly Grant tundlng of •ctivitie5 Support eosts 15ee note 71 Total Ralsing funds 37.803 25.000 7.274 70.077 2025 Artivitles undertaken dirertly Grant fundlng of actlvltles Support costs (see notÈ 71 Total Ralslng funds 33.805 25.000 7,010 65,815 Page 10
British Psoriatic Arthritis Consortium Notes to the Financial Statements (continued) For The Year Ended 31 March 2026 7. Support Costs 2026 2025 Raising funds Raisln9 funds Employee costs Premises expenses General adminlstration 1,014 1.850 4.410 947 1.850 4,213 7,274 7.OLO 8. Indèpendent Examlner's R•muneratlon 2026 2025 Independent examinatlon of the financial statements 1,438 1,398 Debtors 2026 2025 Due wlthin one year Other debtors 1,985 5,713 10. Credltors: Amounts F•lllng Due Withln One Year 2026 2025 Trade credltors 3.162 2,481 11. Movement In Funds As at l April 2025 Asat31 Expendlture March 2026 Income Unrestrirted funds General.. GenÈral unrestricted fund Restrlcted funds 79.272 60.521 170,0771 69.716 Sequence Project 52.648 52.648 Total funds 131,920 60.521 170,0771 122.364 As at l April 2024 Asat31 Expendlturè March 2025 rncome Unrestrlrt4d fvnds General.. Gener61 unrestrfcted fund 112,649 25,388 158,765) 79,272 .CONTINUED Pa9e Ll
British Psoriatic Arthritis Consortium Notes to the Financial Statements (continued) For The Year Ended 31 March 2026 Restrlrted fund5 Sequence Project 59,698 17.0501 52.648 Total funds 172,347 25,388 165,8151 131,920 L2. Related Party Dlstlosures There have been no related party transcations in the pOrting period that requi disctslsu. Page 12
Britlsh Psoriatic Arthritis Consortium Detailed Statement of Flnancial Artivities For The Year Ended 31 March 2026 2026 2025 Yotal funds Tot#1 funds INCOME AND eNDOWMENTS FROM: Donation5 and le9acie8 Donations from individuals 213 142 213 142 other trading art4vltle5 Sponsof5h*ps 60.000 25,000 60.000 25,000 Investments Bank interest receivable 308 246 308 246 $0,521 25.388 expENDITURE ON: Ralslng funds Admlnlstratlon fees Abstract Award Patient Partner expenses crse expenses Project expenses 50th Anniversiary Meetlrng Grants to Institutions Travel and subsistence expense5 Rent Ccynputer 50ftware, consumables and rnalntenance Insurance 15,9071 {6801 11051 110,0401 (4,5611 15001 1510) (9.064} 119,1701 121.07L} 125.0001 {1.014} {1,850} 1924) 1368) {911 1237) {1.438) 12751 19601 11171 125,0(K)} 1947) (1,850) 1728) {368) {2991 12001 11,3981 12201 {9301 1701 Printing, postage and stationery Telecommunications and data costs Independent examiner's fees Subscriptions Bookkeeping fees Bank charyes 170.0771 165.8151 170.0771 165,8151 NET EXPENDITURE 19,5561 140.4271 Page L3